With an outcomes-based design 1 and reduced procedural complexity 2, it’s designed to meet previously unmet surgical needs in hip fracture treatment. The TFN-ADVANCED Nailing …

Feb 7, 2024 · Data from FRONTIER 1, a Phase 2b clinical trial, show JNJ-2113, the first and only targeted oral peptide that selectively blocks the IL-23 receptor, achieved the primary and all …

2 days ago · Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.

Nov 19, 2024 · JNJ-2113's potential as a first-in-class oral therapy for psoriasis is supported by its efficacy, tolerability, and IL-23 receptor targeting. Future studies will evaluate JNJ-2113 in …

Mar 9, 2024 · JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data …

Mar 8, 2025 · Johnson Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head …

Jul 4, 2023 · JNJ-2113 is a novel oral IL-23R antagonist peptide that binds with high affinity to the IL-23R and has properties that allow it to be absorbed with oral dosing. 2,3 The IL-23/IL-23R …

Find the latest Johnson & Johnson (JNJ) stock quote, history, news and other vital information to help you with your stock trading and investing.

Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year. Information about our Innovative Medicine patent portfolio.

TFN-ADVANCEDTM PROXIMAL FEMORAL NAILI. r 2022 Overview Since its introduction in 2015, the TFN-ADVANCEDTM Proximal Femoral Nailing System (TFNA) has sold over …